Bank of America Securities Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Ionis Pharmaceuticals, with a price target of $97.00. The company’s shares closed yesterday at $81.51.

TipRanks Cyber Monday Sale

• Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
• Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Gerberry covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, and Jazz Pharmaceuticals. According to TipRanks, Gerberry has an average return of 15.0% and a 60.49% success rate on recommended stocks.

In addition to Bank of America Securities, Ionis Pharmaceuticals also received a Buy from TD Cowen’s Yaron Werber in a report issued on December 3. However, on December 7, TR | OpenAI – 4o reiterated a Hold rating on Ionis Pharmaceuticals (NASDAQ: IONS).

Based on Ionis Pharmaceuticals’ latest earnings release for the quarter ending October 28, the company reported a quarterly revenue of $156.72 million and a GAAP net loss of $128.61 million. In comparison, last year the company earned a revenue of $133.81 million and had a GAAP net loss of $140.48 million

Based on the recent corporate insider activity of 127 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IONS in relation to earlier this year. Last month, Joan Herman, a Director at IONS sold 44,000.00 shares for a total of $3,173,720.00.